Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers
Our findings provide a promising clinical approach for preventing and treating cardiotoxicity induced by ICIs, dissociating the antitumor efficacy of ICI-based therapies from their cardiotoxic side effects.
Authors
- Pengchong Du
- Yunzhe Wang (ORCID: https://orcid.org/0000-0003-0599-6989)
- Junnan Tang (ORCID: https://orcid.org/0000-0002-4340-5337)
- Jiamin Gao
- Ge Zhang (ORCID: https://orcid.org/0000-0002-3116-3246)
- Qing Chen (ORCID: https://orcid.org/0000-0002-7919-5159)
- Ping Li (ORCID: https://orcid.org/0000-0003-0332-867X)
- Lu Yang (ORCID: https://orcid.org/0000-0001-5843-5478)
- Jinying Zhang
- Zhenwei Wang (ORCID: https://orcid.org/0000-0002-1627-6082)
- Zhen Qin (ORCID: https://orcid.org/0000-0002-1835-1453)
- Han Yang
- Dashuai Wang (ORCID: https://orcid.org/0000-0003-2575-1524)
- Zhaowei Sun (ORCID: https://orcid.org/0000-0002-3195-0186)
- Yachen Hou
Institutions
- Zhengzhou University (CN)
- Third Affiliated Hospital of Zhengzhou University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Henan Provincial Center for Disease Control and Prevention (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010127
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 9.41
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Zhengzhou University
- Recruitment Program of Global Experts
- First Affiliated Hospital of Zhengzhou University
- Wuhan Union Hospital